期刊文献+

米氮平、氯丙咪嗪、氟西汀抗抑郁作用和副反应的比较 被引量:21

下载PDF
导出
摘要 目的 :比较米氮平、氯丙咪嗪、氟西汀的抗抑郁作用和副反应。方法 :将 96例符合CCMD 3诊断标准的抑郁症患者 2 4项HAMD得分≥ 2 4分 ,随机分别给予口服米氮平 (A组 )、氯丙咪嗪 (B组 )、氟西汀 (C组 )。研究全程为 4周 ,在治疗后的第 4、7、14、2 8天分别评定HAMD、TESS。所得数据分别进行方差分析及Ridit分析。结果 :3组患者在治疗后的第 7、14、2 8天HAMD得分下降都非常显著 (P <0 0 1) ,经两两比较差异无显著意义 (P >0 0 5 )。A组患者第 4天HAMD得分及焦虑 /躯体化因子分值均显著低于入组时 (P <0 0 5 )。B组TESS得分在第4、7、14、2 8天时分别显著及非常显著地高于A组与C组 (P <0 0 5 ,<0 0 1)。A组和B组患者都有抗胆碱能副反应出现 ,但A组远低 (轻 )于B组 ,C组主要是消化道的副反应。 3组患者均未观察到有血象、肝、肾功能损害。结论 :米氮平抗抑郁疗效确切 ,副反应小 ,并有抗焦虑。
出处 《实用医学杂志》 CAS 2004年第3期318-319,共2页 The Journal of Practical Medicine
  • 相关文献

参考文献4

  • 1熊鹏,宣熙,王继才.米氮平治疗抑郁症的临床疗效[J].上海精神医学,2003,15(2):93-95. 被引量:32
  • 2Ono H, Shirakawa O, Nishiguchi N, et al. Serotonin 2A receptor gene polymorphism is not associated with completed suicide. J Psychiatr Res,2001, 35(3):173 - 176.
  • 3Massat 1, Souery D, Lipp O, et al. Aeuropean multticenter association study of 5-HTR2A receptor polymorphism in bipolar affective disorder.Am J Med Genet, 2000, 96(2) : 136 - 139.
  • 4Chee IS. Lee sw, Kim JL, et al. 5-HT2A receptor gene promoter polymorphism-1438 A/G and bipolar disorder. Psychiatr Genet, 2001, 11(3):111- 115.

二级参考文献13

  • 1[1]Do Boer t, Ruit GSF, Berendsen HHG. The alph αa selective adrenoceptor antagonist Org 3770 (mirtazapine, Remeron) enhances noradrenergic and serotonergic transmission. Hum Psychopharmcol,1995, 10 (suppl2) : 107~118
  • 2[2]De Boer T. The effects of mirtazapine on central noradrenergic and serotonergic neurotransmission. Int Clin Psychopharmacol, 1995, 10(suppl4) : 19~23
  • 3[3]Stahl S, Zivkov M, Reimitz PE, et al. Meta-analysis of randomized,double-blind, placebo-controlled, efficacy and safety studies of mirtazapine versus amitriptyline in major depression. Acta Psychiatr Scand (suppl), 1997, 391 : 22~30
  • 4[4]Leinonen E, skarstein J, Behnke K, et al. Efficacy and tolerability of mirtazapine versus citalopram: a double-blind, randomized study in patients with major depressive disorder. Nordic Antidepressant Study Group. Int Clin Psychopharmacol, 1999, 14 : 329~337
  • 5[5]Wheatley DP, Van Moffaert M, timmerman L, et al. Mirtazapine: efficacy and tolerability in comparison with fluoxetine in patients with moderate to severe major depressive disorder. Mirtazapine-Fluoxetine Study Group. J Clin Psychiatry, 1998, 59: 306~312
  • 6[6]Kasper S. Clinical efficacy of mirtazapine: a review of meta-analyses of pooled data. Int Clin Psychopharmacol, 1995, 10 (suppl 4) : 25~35
  • 7[7]Hoyberg OJ, Maragakis B, Mullin J, et al. A double-blind multicentre comparison of mirtazapine and amitriptyline in elderly depressed patients. Acta Psycho Scand, 1996, 93 : 184~190
  • 8[8]Benkert O, Szegedi A, Kohnen R. Mirtazapine compared with paroxetine in major depression. J Clin Psychiatry, 2000 Sep, 61 (9) : 656~663
  • 9[9]Goodnick PJ, Puig A, DeVane CL, et al. Mirtazapine in major depression with comorbid generalized anxiety disorder. J Clin Psychiatry, 1999 Jul, 60(7) : 446~448
  • 10[10]Holm KJ, Markham A. Mirtazapine: a review of its use in major depression. drugs, 1999, 57: 607~631

共引文献31

同被引文献163

引证文献21

二级引证文献82

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部